IP Library Granted Patent US 8,043,805
Granted Patent B2
US 8,043,805 · App. 12/422,859 · Granted Oct 25, 2011

Detection of high grade dysplasia in cervical cells

Assignee: Vysis, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,043,805
App. No.
12/422,859
Granted
Oct 25, 2011
Kind
B2
Abstract

Methods of using probes and probe sets for the detection of high grade dysplasia and carcinoma in cervical cells are described. Methods of the invention include hybridizing one or more chromosomal probes to a biological sample obtained from a subject and detecting the hybridization pattern of the chromosomal probes to the sample to determine whether the subject has high grade dysplasia or carcinoma. Methods of the invention also include preliminary screening the cells for a marker associated with a risk for cancer, and preferably involves screening for HPV infected cells by in situ hybridization using an HPV probe mixture.

Claims (30)

1. A method for screening for cervical high grade squamous intraepithelial lesion (HSIL) in a human subject, the method comprising:

a. obtaining a cervical sample containing a plurality of cervical cells from the subject;

b. contacting the sample with a set of two or more chromosomal probes comprising chromosomal probes specific for loci 8q24 and 20q13 able to detect HSIL under conditions sufficient to enable hybridization of the probes to any chromosomes in the sample; and,

c. detecting the hybridization pattern of the chromosomal probes to the plurality of cells in the sample, wherein said hybridization pattern is indicative of amplification of loci 20q13 and 8q24 and correlating said amplification of loci 20q13 and 8q24 with the presence of cervical HSIL in said subject.

2. The method of claim 1 , wherein the sample comprises a biopsy.

3. The method of claim 1 , wherein the sample comprises a cervical smear or cervical scrape sample.

4. The method of claim 1 , wherein the chromosomal probes are fluorescently labeled.

5. The method of claim 1 , wherein the set of two or more chromosomal probes additionally comprises probes specific for 3q26, Xp22 and CEP 15.

6. The method of claim 1 , wherein the set of two or more chromosomal probes additionally comprises probes specific for 3p21, 3p14 and CEP 3.

7. The method of claim 1 wherein cells from the cervical sample are prescreened for a marker associated with risk for cancer.

8. The method of claim 1 wherein cells from the cervical sample are prescreened for infection by HPV.

9. The method of claim 8 wherein the sample is screened for infection by one or more of the high risk HPV types selected from the group consisting of 16, 18, 31, 33, 35, 52 and 58.

10. The method of claim 1 wherein cells from the cervical sample are prescreened for the presence of a cell cycle protein or a cell proliferation marker.

11. The method of claim 10 wherein the cell cycle protein is p16 or Cyclin E.

12. The method of claim 10 wherein the cell proliferation marker is the protein Ki67 or the protein PCNA.

13. A method for screening for cervical HSIL in a human subject, the method comprising:

a. obtaining a cervical sample containing a plurality of cervical cells from the subject;

b. contacting the sample with a set of two or more chromosomal probes comprising chromosomal probes specific for loci 8q24 and 20q13 able to detect HSIL and a mixture of HPV probes under conditions sufficient to enable hybridization of the probes to any chromosomes in the sample and sufficient to enable detection of any HPV infected cells present in the sample;

c. detecting the presence of HPV infected cells in the sample;

d. determining hybridization pattern of the chromosomal probes in the HPV infected cells in the plurality of cervical cells in the sample, wherein said hybridization pattern is indicative of amplification of loci 20q13 and 8q24 and correlating said amplification of loci 20q13 and 8q24 with the presence of cervical HSIL.

14. The method of claim 13 wherein the mixture of HPV probes consists of probes substantially complementary to full coding sequence for each of HPV-16, HPV-18, HPV-30 and HPV-58.

15. The method of claim 13 , wherein the set of two or more chromosomal probes additionally comprises probes specific for 3q26, Xp22 and CEP 15.

16. The method of claim 13 , wherein the set of two or more chromosomal probes additionally comprises probes specific for 3p21, 3p14 and CEP 3.

17. The method of claim 15 wherein the set of two or more chromosomal probes comprises probes to the TERC locus at 3q26, the cmyc locus at 8q24 and the centromere of chromosome 8.

18. The method of claim 14 wherein hybridization conditions are sufficient to detect the presence of any of HPV-31, HPV-33, HPV-35, HPV-39, HPV-52, HPV-56, HPV-58, HPV-59, HPV-26, HPV-53, and HPV-66.

19. The method of claim 14 , wherein each of the HPV probes in the mixture comprise a biotin label.

20. The method of claim 16 wherein the detecting of the presence of HPV infection and the determination of the hybridization pattern of the chromomal probes is performed using digital imaging.

21. The method of claim 16 wherein presence of a hybridization pattern indicative of the presence of cervical HSIL is identified in three or more HPV infected cells.

22. The method of claim 20 wherein presence of a hybridization pattern indicative of the presence of cervical HSIL is identified in one or more HPV infected cells.

23. The method of claim 1 , wherein the sample is contacted with two to not more than four chromosomal probes.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2014
From: KING, WALTER; MORRISON, LARRY E.; SEELIG, STEVEN A.; SOKOLOVA, IRINA A.; ALGECIRAS-SCHIMNICH, ALICIA
To: VYSIS, INC.
Reel/Frame 034184/0574 →
CHANGE OF NAME Recorded Nov 17, 2014
From: VYSIS, INC.
To: ABBOTT MOLECULAR INC.
Reel/Frame 034255/0431 →
Continuity (3)
Continuation 10857859 · Jun 2, 2004
Continuation In Part 10457639 · Jun 9, 2003
Related Publication 20090269768A1 · Oct 29, 2009